The Fund Grade · free · no account needed
What grade does BIOPX get?
Morningstar rates funds on what they returned. We grade them on where their money sits today: how much of the book overlaps with the converged buys of the top specialist stock pickers.
Fundprints Fund Grade · as of 2026-10-01
Baron Opportunity Fund Retail Shs
#24 of 500 graded active funds · blend · large segment peer group
The point · specialist footprint
BIOPX puts more of its book behind proven specialists than 97% of graded funds.
Bottom 20%
Bottom 40%
Middle
Top 40%
● Top 20%
That has mattered: over the past 2.7 years, funds on this rung beat bottom-rung funds by about 3.8% per quarter, and beat the S&P in 43% of fund-quarters versus their 22%. The evidence argues this fund earns its seat.
10,000+ funds tracked · the graded specialists among them drive every read
The grade scores this fund's specialist share, the slice that overlaps what the top 1% of proven funds are building. We ignore index ballast and names outside our edge on purpose: that slice is small, and it's what decides the outcome.
BIOPX vs the Honor Roll · share card ↗Conviction exposure
65.7%
of the book in specialist-converged names
Late-stage weight
22.3%
of the book in Crowded or Fading names
Active share
87.1%
how far it strays from the index
The best grades have beaten the worst by about +5% a year since we began grading. The gap held in 9 out of 10 months. Measured on filings as they were published, no hindsight.
Inside the book: top names by stage · as of 2026-10-20
We email you the day it crosses 50% crowded, and where you stand every month.
Graded monthly from point-in-time filings. A description of where the money sits, not a recommendation. Evidence, not advice.
The read · what to do with it
Baron Opportunity Fund ranks 24th out of 500 graded funds with an A grade, and 65.7% of its weight sits with specialist investors whose footprint is in the top 20% among peers. The most striking tension is that AVGO and TSLA together make up nearly 12% of the fund yet specialists are actively fading both positions. Early-stage ideas like GDS and FPS show the fund can still get in early, but those fading heavyweights are the story right now.
→ Watch AVGO and TSLA closely, as specialists fading two positions that together represent nearly 12% of the fund is a meaningful signal.
→ Compare the early-stage weight in GDS and FPS against the fading weight in AVGO and TSLA to judge whether the fund is genuinely repositioning.
Support leaving these positions
Read from today's disclosed book. Evidence, not advice.